Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A
暂无分享,去创建一个
V. A. Stewart | S. D. de Vlas | Joe D. Cohen | O. Ofori-Anyinam | M. Kortepeter | R. Sauerwein | E. Bergmann-Leitner | C. Ockenhouse | E. Angov | C. Long | W. Ballou | K. Kester | C. Hermsen | D. Lanar | S. Dutta | M. Dowler | D. Heppner | K. Tucker | C. Diggs | L. Soisson | Elissa M. Malkin | Michele D Spring | J. Cummings | M. Dubois | U. Krzych | E. Tierney | L. Ware | Meng-yuan Shi | Jack L. Williams | L. Juompan | S. Bittner | Randall Reidler | R. Nielsen | Elissa Malkin | Joe D. Cohen | S. J. Vlas | G. Mark | Kortepeter | C. Cornelus | Hermsen | L. Jack | Williams | Jack L. Williams
[1] A. Thomas,et al. Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02 , 2008, PloS one.
[2] M. Demoitié,et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. , 2008, Vaccine.
[3] V. A. Stewart,et al. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. , 2008, Vaccine.
[4] V. A. Stewart,et al. Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial , 2008, PloS one.
[5] M. Tanner,et al. A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers , 2007, PloS one.
[6] P. Chomez,et al. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.
[7] A. Batchelor,et al. Structural basis of antigenic escape of a malaria vaccine candidate , 2007, Proceedings of the National Academy of Sciences.
[8] Marie-Claude Dubois,et al. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. , 2007, Vaccine.
[9] V. A. Stewart,et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. , 2007, Vaccine.
[10] M. Fay,et al. Phase 1 Study of Two Merozoite Surface Protein 1 (MSP142) Vaccines for Plasmodium falciparum Malaria , 2007, PLoS clinical trials.
[11] David L. Smith,et al. Dynamics of Polymorphism in a Malaria Vaccine Antigen at a Vaccine-Testing Site in Mali , 2007, PLoS medicine.
[12] V. A. Stewart,et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. , 2006, Vaccine.
[13] D. Webster,et al. A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge , 2006, Infection and Immunity.
[14] K. Sperber,et al. Phenotypic diversity in delayed drug hypersensitivity: an immunologic explanation. , 2006, The Mount Sinai journal of medicine, New York.
[15] E. Bergmann-Leitner,et al. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. , 2006, The American journal of tropical medicine and hygiene.
[16] Joe D. Cohen,et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. , 2006, Vaccine.
[17] F. Spertini,et al. Academic Editor: Brian Greenwood, University of London, United Kingdom , 2005 .
[18] D. Webster,et al. Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria1 , 2005, The Journal of Immunology.
[19] D. Webster,et al. Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. , 2005, The American journal of tropical medicine and hygiene.
[20] Hong Zhou,et al. Phase 1 Clinical Trial of Apical Membrane Antigen 1: an Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria , 2005, Infection and Immunity.
[21] V. A. Stewart,et al. Characterization of a human reference standard for antibody to Plasmodium falciparum merozoite surface protein 1(42). , 2005, The American journal of tropical medicine and hygiene.
[22] V. A. Stewart,et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. , 2005, Vaccine.
[23] D. Conway,et al. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. , 2004, Vaccine.
[24] Joe D. Cohen,et al. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. , 2004, Vaccine.
[25] S. D. de Vlas,et al. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. , 2004, The American journal of tropical medicine and hygiene.
[26] Markus S. Mueller,et al. A Role for Apical Membrane Antigen 1 during Invasion of Hepatocytes by Plasmodium falciparum Sporozoites* , 2004, Journal of Biological Chemistry.
[27] A. Hill,et al. Malaria vaccine developments , 2004, The Lancet.
[28] A. Thomas,et al. Apical Membrane Antigen 1, a Major Malaria Vaccine Candidate, Mediates the Close Attachment of Invasive Merozoites to Host Red Blood Cells , 2004, Infection and Immunity.
[29] W. Ripley Ballou,et al. Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ1 , 2003, The Journal of Immunology.
[30] B. Keegan,et al. Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria , 2002, Infection and Immunity.
[31] S. Ralph,et al. Independent Translocation of Two Micronemal Proteins in Developing Plasmodium falciparum Merozoites , 2002, Infection and Immunity.
[32] J. K. Moch,et al. Purification, Characterization, and Immunogenicity of the Refolded Ectodomain of the Plasmodium falciparum Apical Membrane Antigen 1 Expressed in Escherichia coli , 2002, Infection and Immunity.
[33] E. Linders,et al. Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. , 2001, Molecular and biochemical parasitology.
[34] S. Howell,et al. Proteolytic Processing and Primary Structure ofPlasmodium falciparum Apical Membrane Antigen-1* , 2001, The Journal of Biological Chemistry.
[35] B. Nahlen,et al. Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII. , 2001, The American journal of tropical medicine and hygiene.
[36] R. Anders,et al. Specificity of the Protective Antibody Response to Apical Membrane Antigen 1 , 2001, Infection and Immunity.
[37] J. Palensky,et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. , 2001, The Journal of infectious diseases.
[38] Q. Cheng,et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. , 2000, Vaccine.
[39] B. Nahlen,et al. Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria , 1996, Infection and immunity.
[40] I. Schneider,et al. T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens. , 1995, Journal of immunology.
[41] A. Waters,et al. Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen , 1988, Parasite immunology.
[42] Milburn Cl,et al. The Walter Reed Army Institute of Research. , 1961 .
[43] C. Dye,et al. World Malaria Report, 2008. , 2008 .
[44] M. Fried,et al. Malaria in the pregnant woman. , 2005, Current topics in microbiology and immunology.
[45] R. Anders,et al. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. , 1998, Vaccine.
[46] S. Hoffman,et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. , 1986, The American journal of tropical medicine and hygiene.